August 3rd, 2010
Building on Your Success
Harlan M. Krumholz, MD, SM
Welcome to the remodeled CardioExchange: We hope you like our new look! In our efforts to develop a website that promotes learning and discussion about our rapidly evolving field, we’ve been listening and learning.
We have many new features. Some of the most prominent are:
- You can now see all of the activity on the site from the new homepage, including newly uploaded posts and comments.
- You can now make anonymous comments. Many people think this may foster more discussion. We are eager to see whether that happens.
- You can now “follow” the people, blogs, and topics that interest you the most and receive email notifications when new activity takes place.
With all these changes, our philosophy and approach remain the same. We want to be a credible, trustworthy source of information and a venue for the exchange of views and perspectives. We want to give you access to the various ways people are thinking about new (and old) information in medicine — and provide you the opportunity to learn from each other.
And we are not done listening. We will continue to learn from what you say on and do with CardioExchange, as well as from your direct feedback. Ultimately, the site is a facilitator; it is the people who make CardioExchange. We will be encouraging you to be more involved and to try out the various features. And we ask you to bring in others to participate. The site ultimately belongs to the community — and it is up to all of us to define it.
Categories: General
Tags: CardioExchange, social media
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Survodutide Once Weekly for the Treatment of Adults with Obesity August 20, 2026In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo.
- The Broader Dangers of Abandoning SGM Health Research August 20, 2026When research is defunded not for scientific reasons but because it has become politically inconvenient, the ensuing damage is wide ranging, affecting far more than the disfavored topics and populations.
- A New Approach to Lowering LDL Cholesterol August 13, 2026The pioneering work of Vafai and colleagues, reported in this issue of the Journal,1 paves the way for a new type of low-density lipoprotein (LDL) cholesterol–lowering therapy called VERVE-102: a therapy that appears to lower LDL cholesterol levels enough to reduce the risk of atherosclerotic cardiovascular...
- Last Man Running August 13, 2026As the health of his brother and running buddy rapidly declines and he faces his own health scares, a physician feels compelled — and grateful — to keep moving forward.
- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia August 13, 2026The authors report reductions in PCSK9 and LDL cholesterol levels and no dose-limiting toxic effects in persons with hypercholesterolemia treated with VERVE-102, a base editor targeting PCSK9.
- Survodutide Once Weekly for the Treatment of Adults with Obesity August 20, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
